<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697801</url>
  </required_header>
  <id_info>
    <org_study_id>MAP0010-CL-P201</org_study_id>
    <nct_id>NCT00697801</nct_id>
  </id_info>
  <brief_title>Study of MAP0010 in Asthmatic Children and Adolescents</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group, Phase 2 Study Investigating the Efficacy, Tolerability and Pharmacokinetics of MAP0010 in Asthmatic Children and Adolescents Over 6 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics
      of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Daytime Composite Symptom Score</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Nighttime Composite Symptom Score</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1% Predicted</measure>
    <time_frame>baseline, week 6</time_frame>
    <description>The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>MAP0010 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAP0010 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0010 low dose</intervention_name>
    <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
    <arm_group_label>MAP0010 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0010 high dose</intervention_name>
    <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
    <arm_group_label>MAP0010 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female asthmatic children/adolescents

          -  1 to 18 years of age

          -  FEV1 greater than or equal to 50% predicted normal (where obtainable)

          -  Stable but symptomatic

          -  Diagnosis of asthma (per NIH criteria) at least 3 months before screening OR
             documented exacerbation or worsening of asthma or symptoms suggestive of asthma
             including nocturnal asthma, within 6 months of screening OR documented SAB use more
             than or at least once for symptom relief during the 4 days of run in with a total
             symptom score greater than or equal to 1 OR greater than or equal to 1 night disturbed
             due to asthma symptoms in previous month.

        Exclusion Criteria:

          -  Any other significant childhood illness.

          -  Participated in any investigational clinical trial within the 30 days prior to
             screening.

          -  Use of any corticosteroid within 2 weeks of screening.

          -  Use of oral corticosteroid within 30 days of screening or prolonged use of oral
             corticosteroids within 12 weeks of screening.

          -  Use of inhaled long acting bronchodilators.

          -  Presumptive or documented history of upper or lower respiratory infection within 2
             weeks before screening.

          -  Any history of acute or severe asthma attack requiring ICU admission or ventilatory
             support.

          -  History suggestive (or diagnosis) of other concomitant lung disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>August 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2013</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MAP0010 High Dose</title>
          <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>MAP0010 Low Dose</title>
          <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline characteristics are summarized on the Intent-to-treat population (those patients with at least 1 on treatment efficacy evaluation including 1 electronic diary entry).</population>
      <group_list>
        <group group_id="B1">
          <title>MAP0010 High Dose</title>
          <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>MAP0010 Low Dose</title>
          <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="65"/>
            <count group_id="B4" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="4.76"/>
                    <measurement group_id="B2" value="10.5" spread="4.75"/>
                    <measurement group_id="B3" value="10.2" spread="4.52"/>
                    <measurement group_id="B4" value="10.3" spread="4.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Daytime Composite Symptom Score</title>
        <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
        <time_frame>baseline, week 6</time_frame>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>MAP0010 High Dose</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>MAP0010 Low Dose</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Composite Symptom Score</title>
          <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Daily composite symptom score is based on the average of the individual symptom scores for a day. Daytime composite symptom score is defined as average of the last 5 days' daily composite symptom scores within the last 5 days immediately preceding the end day of that week. The range for the daytime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
          <population>Patients with available data at specified time points are included in the analysis population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.90"/>
                    <measurement group_id="O2" value="2.8" spread="1.75"/>
                    <measurement group_id="O3" value="2.6" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.80"/>
                    <measurement group_id="O2" value="-1.4" spread="1.48"/>
                    <measurement group_id="O3" value="-0.6" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Nighttime Composite Symptom Score</title>
        <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
        <time_frame>baseline, week 6</time_frame>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>MAP0010 High Dose</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>MAP0010 Low Dose</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nighttime Composite Symptom Score</title>
          <description>The individual symptoms at each time point to be monitored are: cough, wheeze, and shortness of breath.
The individual symptoms were scored using a four point scale:
0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms
Nightly composite symptom score is based on the average of the individual symptom scores for the night. Nightime composite symptom score is defined as average of the last 5 days' nightly composite symptom scores within the last 5 nights immediately preceding the end day of that week. The range for the nighttime composite symptom score is 0 (no symptoms) to 3 (severe symptoms). A negative change indicates an improvement of symptoms and a positive change indicates a worsening of symptoms.</description>
          <population>Patients with available data at specified time points are included in the analysis population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.96"/>
                    <measurement group_id="O2" value="2.4" spread="1.75"/>
                    <measurement group_id="O3" value="2.4" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.00"/>
                    <measurement group_id="O2" value="-1.2" spread="1.42"/>
                    <measurement group_id="O3" value="-0.4" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1% Predicted</title>
        <description>The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).</description>
        <time_frame>baseline, week 6</time_frame>
        <population>Patients with available data at specified time points are included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>MAP0010 High Dose</title>
            <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>MAP0010 Low Dose</title>
            <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1% Predicted</title>
          <description>The forced expiratory volume in 1 second (FEV1) is the amount forced of air exhaled in 1 second. The percent predicted is calculated for age, gender, and height. Subjects had to perform at least 3 acceptable maneuvers into a spirometer. An increase indicates an improvement (a greater volume of air expired).</description>
          <population>Patients with available data at specified time points are included in the analysis population.</population>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="11.45"/>
                    <measurement group_id="O2" value="73.8" spread="13.10"/>
                    <measurement group_id="O3" value="65.9" spread="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 6 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="9.87"/>
                    <measurement group_id="O2" value="6.3" spread="7.73"/>
                    <measurement group_id="O3" value="5.9" spread="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All patients who received any study drug and who had at least one post safety evaluation were included in the adverse event analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>MAP0010 High Dose</title>
          <description>a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>MAP0010 Low Dose</title>
          <description>a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo delivered by nebulization twice daily for 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Scientific Affairs</name_or_title>
      <organization>MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan</organization>
      <phone>650-386-3100</phone>
      <email>dkellerman@mappharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

